Actively Recruiting
Evaluation of IBI343 Combined With Chemotherapy for Patients With Advanced Pancreatic Cancer
Led by Zhejiang Cancer Hospital · Updated on 2026-07-09
56
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of IBI343 combined with chemotherapy in patients with advanced pancreatic cancer who have CLDN18.2-positive tumors and have previously received first-line gemcitabine-based therapy. This Phase IbII trial includes a dose-escalation safety introduction phase followed by an expansion phase to further explore the treatments impact. In the Phase Ib safety introduction, two groups receive different combinations Cohort A receives IBI343 plus capecitabine orally twice daily for 14 days every 3 weeks, starting with specific doses and adjusting based on tolerance. Cohort B receives IBI343 combined with capecitabine and oxaliplatin intravenously every 3 weeks for up to 8 cycles of oxaliplatin. Dose levels may be adjusted based on observed toxicities, and expansion phases proceed sequentially once safety is established. Participants undergo regular imaging using RECIST v1.1 criteria to assess tumor response. Treatment continues until disease progression, unacceptable toxicity, withdrawal, loss of follow-up, or death. After stopping study treatment, safety and survival are monitored. Key outcomes measured include objective tumor response rates and treatment-related adverse events, with survival tracked for up to 24 months after randomization. All assessments occur during scheduled visits throughout the study duration.
CONDITIONS
Brief Title
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
Research Team
J
jieer ying
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here